Previous 10 | Next 10 |
BELTSVILLE, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will hos...
BELTSVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will host...
NextCure (NXTC) appoints Dr. Han Myint, MD, FACP as chief medical officer. Prior to joining NextCure, Dr. Myint held senior roles at both Celgene and NexImmune.Dr. Myint has over 20 years of experience in both academia and the biopharma industry. ȁ...
BELTSVILLE, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment o...
NextCure ([[NXTC]] -11.1%) provides an update on the clinical trial program for NC318, its first-in-class immunomedicine against Siglec15 (or S15), a novel immunomodulatory target.An ongoing Phase 2 trial is being modified for S15 selection and the company expects to begin pre-selecting ...
BELTSVILLE, Md., Dec. 17, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the c...
BELTSVILLE, Md., Nov. 23, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will part...
Our proprietary POWR Ratings system evaluates stocks on a variety of metrics. It recently downgraded several stocks to "Sell" or "Strong" Sell ratings, including Macy's (M), NantKwest (NK), Oxford Industries (OXM), and NextCure (NXTC). Read more to learn why you should avoid them. The ...
NextCure (NXTC): Q3 GAAP EPS of -$0.59 misses by $0.02.Cash, cash equivalents and marketable securities of $291.2M.Press Release For further details see: NextCure EPS misses by $0.02
BELTSVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported third quarter ...
News, Short Squeeze, Breakout and More Instantly...
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings...
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43% Data to be presented June 1, 2024,...
Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to fund operations into second half of 2026 BELTSVILLE...